Positive Phase 2b Trial of Pharmalink's Nefecon in IgA Nephropathy Selected for Presentation at Leading Kidney Disease Conference

Pharmalink AB announces the appointment of a new Chief Executive Officer

Positive results of Phase 2b Clinical Trial of Pharmalink's Nefecon in Primary IgA Nephropathy published in The Lancet

Pharmalink strengthens board with appointment of Maria Carell as Chair

Pharmalink strengthens team in preparation for Phase III trials with Nefecon in IgA Nephropathy, a progressive inflammatory kidney disease

Pharmalink announces European orphan drug designation for Nefecon® for treatment of IgA Nephropathy, an inflammatory kidney disease

Pharmalink raises SEK100M to advance Nefecon® development as new treatment for kidney disease

Pharmalink announces positive result in Phase 2b Trial of Nefecon®

Pharmalink acquires novel therapeutic product candidate for treating inflammation associated with osteoarthritis

Pharmalink announces an open Investigational New Drug (IND) application for Nefecon®